Lupin Strikes Deal For Anti-TB Drug Pretomanid

Company Plans To Commercialize Highly-Drug Resistant TB Medicine In 140 Countries

Lupin and non-profit organization TB Alliance have entered into a partnership for a new therapy for highly drug-resistant tuberculosis, pretomanid, to be distributed in 140 countries and territories.

TB tuberculosis lung 3D x-ray
Lupin has entered into a partnership for new Therapy for Highly Drug-Resistant TB • Source: Alamy

Lupin has announced acquiring rights to manufacture tuberculosis drug pretomanid from the non-profit drug developer TB Alliance. The deal gives Lupin “a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug ‘BPaL’ regimen,” the partners stated.

The BPaL regimen also includes Johnson & Johnson’s Sirturo (bedaquiline) and Pfizer’s Zyvox (linezolid).

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

Nexus Faces Five Year Wait On Injectable Minocycline

Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

test

uygukgigo

 
• By 

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.